Scottie Scheffler never lost the lead and never gave anyone much of a chance down the stretch Sunday in another relentless ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that applications are now open for its Innovators in Science Award. This prestigious global award ...

TOKYO -- U.S. proxy advisory firm Institutional Shareholder Services (ISS) is recommending shareholders vote against the reelection of Takeda Pharmaceuticals CEO Christophe Weber to the Japanese ...

Salesforce (CRM) announced that Takeda has selected Salesforce Life Sciences Cloud for Customer Engagement to strengthen its involvement with healthcare professionals seamlessly.The company will ...

Takeda teams will have access to real-time insights and intelligent analytics embedded directly in their workflows to drive more streamlined and personalized communication with healthcare ...

No-moat Takeda Pharmaceutical is Japan’s leading pharmaceutical company by revenue. While the firm historically focused on the Japan market, management has undertaken an ambitious overhaul to ...

We are pleased to partner with Takeda as we continue to advance rusfertide to potentially transform the standard of care in PV patients around the world.” “These promising pivotal data ...

SAN FRANCISCO--(BUSINESS WIRE)--Salesforce (NYSE:CRM), the #1 AI CRM, today announced that Takeda has selected Salesforce Life Sciences Cloud for Customer Engagement to strengthen its involvement ...

Takeda (TSE:4502/NYSE:TAK) today announced that applications are now open for its Innovators in Science Award. This prestigious global award, originally launched in 2016, celebrates groundbreaking ...

Takeda Pharmaceutical Company Limited (NYSE:TAK)’s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized by the European Commission on June 3, 2025, for newly diagnosed adult ...

View today's Takeda Pharmaceutical Co., Ltd. stock price and latest 4502 news and analysis. Create real-time notifications to follow any changes in the live stock price.

Takeda could acquire next-generation immunotherapies as it seeks to broaden its offering in the hyper-competitive field of cancer treatment. The Japanese pharma has been building a presence in ...